ArticleCancers2025
Divergent Prognostic Value of Primary Tumor Segmentation Metrics on Baseline FDG PET/CT in Colorectal Cancer.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) remains a major global health concern, with increasing incidence and mortality projected over the coming decades. Despite the central role of staging systems, substantial heterogeneity in clinical outcomes persists among patients within the same stage, highlighting the need for additional prognostic biomarkers. This study aimed to evaluate whether segmentation-derived morphological and metabolic features of the primary tumor could serve as prognostic biomarkers associated with subsequent tumor evolution in CRC.
methodsIn this retrospective, single-center study, 91 patients with histologically confirmed CRC who underwent baseline FDG PET/CT prior to treatment were analyzed. Morphological (tumor shape, cranio-caudal extension, volume) and metabolic (SUVmean, SUVmax, MTV, TLG) parameters of the primary tumor were extracted using 3D segmentation. Clinical benefit (CB) was defined according to RECIST criteria at six months. Logistic regression and Cox proportional hazards models were applied to identify predictors of short- and long-term outcomes, with performance assessed using ROC curves and Kaplan-Meier survival analyses.
resultsCranio-caudal extension was the strongest prognostic biomarker of short-term clinical benefit (AUC = 0.89), with a threshold of 6.2 cm discriminating favorable from unfavorable outcomes. In multivariate analysis, early UICC stage and lower cranio-caudal extension were independently associated with CB. For long-term outcomes, MTV emerged as a consistent prognostic factor: higher MTV predicted shorter progression-free survival (HR = 1.03,
conclusionsSegmentation of the primary tumor on baseline FDG PET/CT provides valuable prognostic information in CRC. While cranio-caudal extension was the strongest prognostic biomarker of short-term treatment response, MTV was independently associated with long-term outcomes, particularly progression-free survival. These findings highlight the complementary prognostic roles of morphological and metabolic tumor features and support the integration of PET/CT-based biomarkers into personalized treatment strategies for colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.